Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pharmacodynamic comparison of different oral P2Y12-receptor inhibitor loading strategies for transitioning from cangrelor in patients undergoing coronary stenting

Trial Profile

Pharmacodynamic comparison of different oral P2Y12-receptor inhibitor loading strategies for transitioning from cangrelor in patients undergoing coronary stenting

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 23 Jun 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cangrelor (Primary) ; Clopidogrel; Prasugrel; Ticagrelor
  • Indications Coronary disorders
  • Focus Therapeutic Use
  • Acronyms ExcelsiorLOAD2

Most Recent Events

  • 01 Feb 2018 Results assessing the impact of Reticulated Platelets on the Antiplatelet Effect of Cangrelor, published in the Thrombosis and Haemostasis
  • 01 Sep 2017 Results published in the ESC Congress 2017: Annual Congress of the European Society of Cardiology
  • 30 Aug 2017 Results presented at the ESC Congress 2017: Annual Congress of the European Society of Cardiology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top